Home Featured 2

Featured 2

Featured posts

Latest

Expanding Efforts Help Address Disparities in Lung Cancer Care

lungcanc

SHAWL: Largest Study of Its Kind Evaluates Sexual Dysfunction in Women With Lung Cancer

Timing of Immune Checkpoint Inhibitors With Respect to Molecular Testing in NSCLC

Brain Metastases in NSCLC: Is Delaying Upfront Radiation a Viable Option?

Lorlatinib in ROS1-Positive NSCLC: A Review of Recent Data

Ki-67 in Pulmonary Neuroendocrine Tumors: Where Do We Stand?

lungcanc

PCI Decreases the Risk of Brain Metastases in Patients with Locally...

lungcanc

2019 IASLC Best of the World Lung Cancer Conference Results in...

lungcanc

The IASLC and the International Thoracic Oncology Nursing Forum: Celebrating Collaboration

lungcanc

PACIFIC Flooded Us with Optimism. Now What?

lungcanc

NCI Director Dr. Norman E. Sharpless Discusses 2019 Budget Plans During...

lungcanc

ICU Care for the Patient with Lung Cancer

lungcanc

Understanding the Effects of Time to Surgery on Upstaging for Stage...

lungcanc

Financial Incentives and Free Treatment Aids for Smoking Cessation in the...

lungcanc

The IASLC Pathology Committee Recommendations for the Use of Diagnostic Immunohistochemistry...

lungcanc

1...567 Page 6 of 7

Meeting News

Leora Horn, MD – IASLC Virtual Presidential Symposium Presentation

Paul Baas, MD – IASLC Virtual Presidential Symposium Presentation

TRACERx Data Show That Tracking MRD With ctDNA Heralds Disease Relapse

cfDNA Analysis Suggests EML4-ALK Variant Does Not Influence Response to Lorlatinib